vs
Side-by-side financial comparison of AGENUS INC (AGEN) and QIAGEN N.V. (QGEN), based on the latest 10-Q / 10-K filings. Click either name above to swap in a different company.
Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and adjuvants designed for use with various vaccines. CPM development is a particularly fast-moving field, since early products have produced unprecedented clinical benefits for patients.
QIAGEN N.V. is a German-founded multinational provider of sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical research. The company operates in more than 35 offices in over 25 countries. QIAGEN N.V., the global corporate headquarter of the QIAGEN group, is located in Venlo, The Netherlands. The main operative headquarters are located in Hilden, Germany. European, American, Chinese, and Asian-Pacific regional headquarters are located ...
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history — bar widths are scaled to the larger of the two companies so you can eyeball the size gap and growth trajectory without doing math. Quarters aligned by calendar period (report date) so offset fiscal years line up.
| Q4 25 | $34.2M | — | ||
| Q3 25 | $30.2M | — | ||
| Q2 25 | $25.7M | — | ||
| Q1 25 | $24.1M | — | ||
| Q4 24 | $26.8M | — | ||
| Q3 24 | $25.1M | — | ||
| Q2 24 | $23.5M | — | ||
| Q1 24 | $28.0M | — |
| Q4 25 | $-10.6M | — | ||
| Q3 25 | $63.9M | — | ||
| Q2 25 | $-30.0M | — | ||
| Q1 25 | $-26.4M | — | ||
| Q4 24 | $-46.8M | — | ||
| Q3 24 | $-67.2M | — | ||
| Q2 24 | $-54.8M | — | ||
| Q1 24 | $-63.5M | — |
| Q4 25 | — | — | ||
| Q3 25 | 97.9% | — | ||
| Q2 25 | 99.1% | — | ||
| Q1 25 | 99.4% | — | ||
| Q4 24 | 99.6% | — | ||
| Q3 24 | 99.4% | — | ||
| Q2 24 | 99.5% | — | ||
| Q1 24 | 99.6% | — |
| Q4 25 | 42.1% | — | ||
| Q3 25 | -15.0% | — | ||
| Q2 25 | -65.0% | — | ||
| Q1 25 | -55.3% | — | ||
| Q4 24 | -96.5% | — | ||
| Q3 24 | -125.5% | — | ||
| Q2 24 | -128.4% | — | ||
| Q1 24 | -117.4% | — |
| Q4 25 | -31.0% | — | ||
| Q3 25 | 211.4% | — | ||
| Q2 25 | -116.8% | — | ||
| Q1 25 | -109.6% | — | ||
| Q4 24 | -174.4% | — | ||
| Q3 24 | -267.7% | — | ||
| Q2 24 | -233.1% | — | ||
| Q1 24 | -226.6% | — |
| Q4 25 | $0.09 | — | ||
| Q3 25 | $1.94 | — | ||
| Q2 25 | $-1.00 | — | ||
| Q1 25 | $-1.03 | — | ||
| Q4 24 | $-1.95 | — | ||
| Q3 24 | $-3.08 | — | ||
| Q2 24 | $-2.52 | — | ||
| Q1 24 | $-3.04 | — |
Financial Flow Comparison
Sankey diagram of revenue → gross profit → operating profit → net profit for each company. Charts shown full-width and stacked so both segment hierarchies are readable side-by-side on desktop and mobile.
